GlobeNewswire

Aegex Technologies Announces Strategy at SPE Offshore Europe 2017 to License Intrinsic Safety Designs and Services to Improve Safety in Oil & Gas Operations

Dela

Calls on Offshore Equipment Manufacturers to Collaborate to Make All Mobile Devices Intrinsically Safe

ABERDEEN, United Kingdom, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Aegex Technologies, the leader in intrinsically safe mobile devices and Internet of Things (IoT) solutions for hazardous area industrial operations, has announced it will license access to its intrinsic safety designs for mobile devices. It will also provide production and testing services to other technology companies serving the oil & gas industry. This strategy leverages Aegex's proprietary intrinsically safe technology to promote collaboration and further innovation in the offshore equipment industry, enabling greater operational safety and efficiency.

Aegex made the announcement today during the SPE Offshore Europe 2017 exhibition, Europe's largest oil & gas exploration and production technology showcase. The company is demonstrating its Aegex10 Intrinsically Safe Tablet and IoT Platform at Stand #2C120 in the event's Technology Zone.

"In the same spirit that the OGTC [The Oil & Gas Technology Centre] here in Aberdeen is aggregating the strengths of technology companies to create new solutions for the offshore industry, Aegex will license and provide other manufacturers access to our intrinsically safe technology, manufacturing facilities and testing grounds," said Aegex CEO Thomas P. Ventulett. "The goal is to make sure every device used in hazardous area operations is the absolute safest possible."

"Intrinsically safe" (IS) devices, such as Aegex's flagship product, the Aegex10 IS Tablet, are certified under international standards for the most potentially explosive conditions, including Zone 1 areas of oil & gas operations. IS devices are designed to limit a concentration of heat or energy that could ignite combustible environments, or "hazardous areas." This is distinct from "explosion-proof" devices, which do not necessarily prevent an explosion but encapsulate it in a protective housing. The benefit of the Aegex design is that equipment is intrinsically safe "from the inside," rather than relying on heavy and expensive explosion-proof form factors.

Aegex will use its proprietary methodologies to assist companies to make offshore solutions intrinsically safe, such as IoT sensors, wearables, accessories, peripherals and scanners that help increase efficiency and safety across operations, from inventory management to equipment maintenance to personnel health.

The new Aegex services include support from the company's research and development division, AegexLabs, which is comprised of an innovation center, engineering and design studio, and manufacturing facilities in Hungary, plus an 800-acre testing facility in the United States, where it tests hazardous area products under realistic conditions.

"Oil and gas operators are increasingly seeking IoT technologies that can help them work more efficiently and more safely. Aegex wants to offer our expertise to other innovators and collectively develop new technologies that can truly reduce costs, increase productivity and enhance safety in offshore industries," Mr. Ventulett added.

Multiple regional and international standards govern the safety and quality of all equipment used in oil & gas operations. These standards - including directives regulated by ATEX, IECEx, UL and other standards bodies - exist to prevent the accidental ignition of combustible atmospheres by an electronic device.

The Aegex10 tablet is globally certified as intrinsically safe for ATEX/IECEx Zone 1 and UL Class I, II, III Division 1 hazardous areas, where flammable materials are likely to be present during normal operations.

About Aegex Technologies
With world headquarters in Atlanta, Ga., USA, European headquarters in Rotterdam, Netherlands, sales offices in Southampton, UK and Dubai, UAE, and distributors worldwide, Aegex provides intrinsically safe mobile and Internet of Things (IoT) solutions for hazardous locations in oil & gas, chemical, pharmaceutical, public safety and other industries with explosive environments.

Contact Aegex for more details. Watch an Aegex overview video to learn more. LinkedIn Twitter Facebook Google+ Instagram

Leigh Villegas
Marketing & Communications Director
+1 229 220 9660
press@aegex.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aegex Technologies via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum